2016-000877-19: A phase 1/2 study in which, DTX-SPL8783, the trial medication will beadministered (alone or in combination with nintedanib) in order to assess the safety, tolerability, pharmacokinetics (distribution of DTX-SPL8783 in the body) and efficacy in patients with advanced malignant tumours. |
|
|
| Ongoing | 1/2 | 65 | Europe | DTX-SPL8783, Concentrate for solution for infusion, Powder and solution for solution for injection | Starpharma Pty Ltd., Starpharma Pty Ltd. | Locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC)., Advanced malignant solid tumours., Diseases [C] - Cancer [C04] | | | | |
2019-004332-36: A Phase 1/2 Modular, Multi-Arm Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of DTX-SPL8783 (DEP docetaxel/DEP-DTX) in Combination with Anti-Cancer Treatments, in Patients with Advanced Malignancies |
|
|
| Not yet recruiting | 1/2 | 63 | Europe | DTX-SPL8783, Gemcitabine, DTX-SPL8783, Powder for solution for infusion, Gemcitabine | Starpharma Pty Ltd, Starpharma Pty Ltd | Advanced malignant solid tumours, Advanced malignant solid tumours, Diseases [C] - Cancer [C04] | | | | |
